Tuesday, October 4, 2022


Biotechnology News Magazine

CellCentric Secures Investment from American Cancer Society’s Impact VC Fund

Funding to advance inobrodib, its ground-breaking p300/CBP targeted therapy

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces it has received funding from BrightEdge, the impact venture capital fund of the American Cancer Society.

The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Investments Limited.

Inobrodib is a first-in-class small molecule inhibitor that impacts twin regulatory proteins p300 and CBP and thus affects a number of established, yet elusive to treat oncogenes (including Myc, IRF4 and the Androgen Receptor). The orally bioavailable drug is transitioning into Phase II clinical trials in multiple indications; castration resistant prostate cancer (mCRPC), haematological malignancies as well as specifically targeted tumours driven by genomic alterations.

CellCentric recently received confirmation from the World Health Organisation for inobrodib as a new International Non-proprietary Name (INN) for CCS1477. The -brodib suffix represents the new class of drug; p300/CBP bromodomain inhibitors. Any subsequent follower drugs with a similar mechanism of action will bear the same novel drug class stem, -brodib.

Alice Pomponio, Managing Director of the American Cancer Society’s BrightEdge said: “We are delighted to be supporting CellCentric’s mission to bring a novel targeted therapy to people with cancer. At BrightEdge we invest in ground-breaking cancer research with the goal to translate them into commercially accessible solutions that put patients front and centre.”

Jason Dinges of Morningside Technology Advisory, and CellCentric Board member, added: “We are proud to continue our support of CellCentric and its mission to bring the first p300/CBP inhibitor to patients. At Morningside we are committed to investing in companies with strong teams and clear plans to deliver on their goals.”

Will West, Chief Executive Officer of CellCentric, commented: “We are very pleased to welcome BrightEdge, alongside our cornerstone investor Morningside, as we continue to pioneer targeted cancer treatment through inhibiting p300/CBP. We now know that our drug can be well tolerated and deliver clear signals of efficacy. The task ahead is to build on that, maximising its impact as a monotherapy and in combination with existing standard of care agents, to treat specific cancer types.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine